Medtech veteran joins at key time of growth for company’s first-in-class CleanCision™ technology, which fights and defends against the sources of surgical site infection
Medtech veteran joins at key time of growth for company’s first-in-class CleanCision™ technology, which fights and defends against the sources of surgical site infection
SAN CARLOS, Calif., July 25, 2018 /PRNewswire/ -- Prescient Surgical, innovator of advanced tools and technologies to fight and defend against the sources of surgical site infection (SSIs), today announced that it appointed Greg Bakan to its Board of Directors.
Bakan currently serves as COO of the Fogarty Institute of Innovation, the nonprofit organization whose mission is to propel innovative medical concepts from initiation to application, providing support and mentorship to promising researchers, developers, and scientists.
“Greg is experienced in market development for novel technologies,” said Jonathan Coe, president and CEO of Prescient Surgical. “His track record of building and scaling successful commercial organizations will be invaluable, as hospitals around the country continue to adopt CleanCision as part of their SSI control bundles.”
Bakan held leadership positions at Fortune 500 and startup companies including Ardian, Emphasys Medical, Nevro, and Fox Hollow Technologies. In aggregate, these startups have generated more than $2.5B in returns to their investors.
“The current healthcare environment favors easy to use technology that provides optimal patient care, while reducing healthcare costs. CleanCision has the potential to deliver in all these areas,” said Bakan. “Prescient is a graduate of the Fogarty Institute and that was another great draw. Serving on boards is another way we provide support to our graduates.”
About CleanCision™
Designed by surgeons and infection control experts, CleanCision is a novel, advanced active cleansing system that uses continuous, consistent wound irrigation and wound protection to fight and defend against the harmful bacteria that cause surgical site infection. Currently approved for use in abdominal surgery, CleanCision gives surgical teams more control over the sources of surgical site infection for better outcomes for patients. Already commercially available in the US, CleanCision recently earned CE mark approval and won the prestigious 2018 Medical Device Excellence Award.
About Prescient Surgical
Based in San Carlos, Calif., Prescient Surgical, Inc. is a medical technology innovator that makes advanced tools and technologies to fight and defend against the sources of surgical site infection. The company is dedicated to making surgery safer, improving the patient experience with surgery, and significantly improving post-operative outcomes. Visit www.prescientsurgical.com and follow us on Twitter at @PrescientSurg
View original content with multimedia:http://www.prnewswire.com/news-releases/prescient-surgical-appoints-fogarty-institute-coo-greg-bakan-to-board-of-directors-300686618.html
SOURCE Prescient Surgical
